AstraZeneca

AstraZeneca diabetes drug granted fast track status for heart failure treatment
AstraZeneca diabetes drug granted fast track status for heart failure treatment
Yahoo/Reuters
AstraZeneca
Farxiga
heart failure
diabetes
FDA
fast track
Flag link:
Real world evidence, digital partnerships and the future of pharma
Real world evidence, digital partnerships and the future of pharma
Pharmaforum
digital pharma
AstraZeneca
RWE
real world evidence
Flag link:
Drug companies pay for exclusive access to UK genetic data
Drug companies pay for exclusive access to UK genetic data
Biopharma Dive
UK
genetic database
Amgen
AstraZeneca
JNJ
GSK
Flag link:
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More
Xconomy
WCLC
lung cancer
KRAS
AMG 510
Amgen
RET
Merck
Keytruda
AstraZeneca
Imfinzi
Blueprint Medicines
Eli Lilly
Flag link:
PhIII lung cancer data signals potential approval for AstraZeneca's Imfinzi
PhIII lung cancer data signals potential approval for AstraZeneca's Imfinzi
Endpoints
AstraZeneca
clinical trials
Imfinzi
Small-Cell Lung Cancer
Flag link:
AstraZeneca aims to pump up Farxiga marketing after cardio outcomes study
AstraZeneca aims to pump up Farxiga marketing after cardio outcomes study
Fierce Pharma
AstraZeneca
Farxiga
drug reps
heart failure
Flag link:
ESMO 2019 preview – PARPs on parade
ESMO 2019 preview – PARPs on parade
EP Vantage
ESMO
PARP inhibitors
Lynparza
AstraZeneca
ovarian cancer
GSK
Zejula
Flag link:
More to come from PARP drugs, says biotech CEO after striking radiotherapy deal with AZ
More to come from PARP drugs, says biotech CEO after striking radiotherapy deal with AZ
Pharmaforum
AstraZeneca
Theragnostics
PARP inhibitors
diagnostics
cancer
Flag link:
ESC: AstraZeneca's SGLT2 med Farxiga flips script on competitors with 26% CV risk cut
ESC: AstraZeneca's SGLT2 med Farxiga flips script on competitors with 26% CV risk cut
Fierce Pharma
AstraZeneca
Farxiga
ESC
Flag link:
AZ gets China nod for Tagrisso in first-line lung cancer
AZ gets China nod for Tagrisso in first-line lung cancer
Pharmaforum
AstraZeneca
China
Tagrisso
non-small cell lung cancer
Flag link:
Heart failure results could unlock key market for Farxiga – AZ
Heart failure results could unlock key market for Farxiga – AZ
Pharmaforum
AstraZeneca
heart failure
diabetes
Farxiga
Flag link:
One year after flop, AstraZeneca's phase 3 lupus trial hits endpoint
One year after flop, AstraZeneca's phase 3 lupus trial hits endpoint
Fierce Biotech
AstraZeneca
clinical trials
anifrolumab
systemic lupus erythematosus
lupus
Flag link:
AstraZeneca’s Fasenra gets FDA ODD status for eosinophilic oesophagitis
AstraZeneca’s Fasenra gets FDA ODD status for eosinophilic oesophagitis
Pharmaceutical Business Review
AstraZeneca
Fasenra
orphan drugs
FDA
eosinophilic esophagitis
Flag link:
AstraZeneca respiratory business gets boost from 3-drug inhaler results
AstraZeneca respiratory business gets boost from 3-drug inhaler results
Yahoo/Reuters
AstraZeneca
Fasenra
Breztri
COPD
Flag link:
U.S. FDA gives fast track status to AstraZeneca's diabetes drug Farxiga
U.S. FDA gives fast track status to AstraZeneca's diabetes drug Farxiga
Yahoo/Reuters
AstraZeneca
Farxiga
chronic kidney disease
FDA
fast track
Flag link:
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
Yahoo/Zacks.com
AstraZeneca
FibroGen
China
roxadustat
chronic kidney disease
Flag link:
AstraZeneca pays Sobi $95M for priority review voucher
AstraZeneca pays Sobi $95M for priority review voucher
Fierce Biotech
AstraZeneca
FDA
Sobi
priority review vouchers
roxadustat
Flag link:
AstraZeneca Imfinzi combination fails advanced lung cancer study
AstraZeneca Imfinzi combination fails advanced lung cancer study
Yahoo/Reuters
AstraZeneca
Imfinzi
advanced non-small cell lung cancer
tremelimumab
Flag link:
AstraZeneca's diabetes drug Farxiga helps patients with heart disease and without diabetes in landmark trial
AstraZeneca's diabetes drug Farxiga helps patients with heart disease and without diabetes in landmark trial
Endpoints
AstraZeneca
Farxiga
cardiovascular disease
Flag link:
AstraZeneca drug heads to phase 2 in pancreatic cancer after small trial extends survival
AstraZeneca drug heads to phase 2 in pancreatic cancer after small trial extends survival
Fierce Biotech
AstraZeneca
pancreatic cancer
DNA
University of Michigan
AZD1775
Flag link:

Pages